


## Fibrinogen Concentrate Market to Reach \$5.9 Billion, Globally, by 2033 at 6.1% CAGR: Allied Market Research

PORTLAND, OR, UNITED STATES, December 16, 2024 / EINPresswire.com/ -- Increasing prevalence of bleeding disorders, rising number of surgical procedures, aging population, and growing focus on interoperability are the major factors which drive the global market growth.



Allied Market Research published a report, titled, "<u>Fibrinogen Concentrate</u>

Market by Product Type (Human Fibrinogen Concentrate, Recombinant Fibrinogen Concentrate, Animal-Derived Fibrinogen Concentrate and Synthetic Fibrinogen Concentrate), Application (Congenital Fibrinogen Deficiency, Surgical Procedures and Other Applications), and End User (Hospitals, Ambulatory Surgical Centers and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the fibrinogen concentrate market was valued at \$3.3 billion in 2023, and is estimated to reach \$5.9 billion by 2033, growing at a CAGR of 6.1% from 2024 to 2033.

## Prime determinants of growth

Increase in prevalence of bleeding disorder cases and rise in aging population are the major factors that drive the growth of the fibrinogen concentrate market. However, the high cost of fibrinogen concentrate hinders market growth. Moreover, technological advancements offer remunerative opportunities for the expansion of the global fibrinogen concentrate market.

Report coverage & details: Report Coverage Details Forecast Period 2024–2033

Base Year

2023

Market Size in 2023

\$3.3 billion

Market Size in 2033

\$5.9 billion

**CAGR** 

6.1%

No. of Pages in Report

216

Segments Covered

Product Type, Application, End user and Region

**Drivers** 

Increasing prevalence of bleeding disorder

Rising number of surgical procedures

Aging population

Opportunities

Technological advancements

Restraints

High cost of fibrinogen concentrate

Segment Highlights

## Human fibrinogen concentrate

Human fibrinogen concentrate is preferred over synthetic and animal-derived fibrinogen due to its higher compatibility with the human body, reduced risk of immunogenic reactions, and better efficacy in clot formation. It also has a more favorable safety profile, making it the standard choice in clinical settings.

Congenital fibrinogen deficiency is more prevalent

Congenital Fibrinogen Deficiency, a rare genetic disorder, leads to abnormal bleeding due to insufficient fibrinogen. This condition is more prevalent in certain populations, necessitating the use of fibrinogen concentrate. This therapy helps restore normal blood clotting, reducing bleeding risks and improving patient outcomes.

Hospitals are the major users of fibrinogen concentrate

Hospitals are the primary users of fibrinogen concentrate, a critical treatment for patients with bleeding disorders, including Congenital Fibrinogen Deficiency. This therapy is essential in emergency and surgical settings to manage bleeding, restore blood clotting, and improve patient

The fibrinogen concentrate market shows robust growth in North America and Europe due to advanced healthcare infrastructure and high prevalence of bleeding disorders. Asia-Pacific is emerging rapidly, driven by increasing healthcare investments and expanding medical facilities, while Latin America and Africa present untapped potential. **Players** Baxter International Inc CSL Behring Enzo Life Sciences, Inc. Ethicon (Johnson and Johnson) GC Biopharma Hualan Biological Engineering Inc. LFB Molecular Innovations Inc. Octapharma AG ProFibrix BV The report provides a detailed analysis of these key players in the global fibrinogen concentrate market. These players have adopted different strategies, such as product launch, expansion, partnership, collaboration and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance,

outcomes effectively.

competitive scenario.

Recent Key Strategies and Developments

**Regional Outlook** 

In December 2023, Grifols reached a strategic alliance with Haier Group and raised approximately \$1.8 billion. The alliance, through Shanghai RAAS (SRAAS), will drive synergies combining Grifols' expertise and capabilities in pharmaceutical solutions and diagnostics with

operating segments, product portfolio, and strategic moves of market players to showcase the

Haier's innovative technology to strengthen and enhance China's healthcare system.

DDDDDDD DDDDDD: https://www.alliedmarketresearch.com/purchase-enquiry/A266127

David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social media: Facebook X

This press release can be viewed online at: https://www.einpresswire.com/article/769352337

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.